Rescue of primary patient leukemia specimens by OKT3 preincubation
| AML no. . | Mouse . | BM . | SPL . | ||||
|---|---|---|---|---|---|---|---|
| Human . | AML . | T . | Human . | AML . | T . | ||
| 1658 | CNTL 1 | 16 | 13 | 81 | 23 | 4 | 82 |
| CNTL 2 | 46 | 13 | 81 | 20 | 4 | 83 | |
| CNTL 3 | 61 | 36 | 57 | 97 | 7 | 54 | |
| OKT3 1 | 42 | 98 | 0 | 1 | 92 | 0 | |
| OKT3 2 | 34 | 99 | 0 | 3 | 97 | 0 | |
| 2837 | CNTL 1 | 30 | 61 | 7 | 3 | 47 | 39 |
| CNTL 2 | 36 | 99 | 0 | 9 | 100 | 0 | |
| OKT3 1 | 37 | 100 | 0 | 1 | 100 | 0 | |
| OKT3 2 | 35 | 99 | 0 | 5 | 99 | 0 | |
| 2844 | CNTL 1 | 81 | 93 | 3 | 91 | 33 | 49 |
| CNTL 2 | 86 | 98 | 1 | 30 | 76 | 19 | |
| CNTL 3 | 92 | 59 | 37 | 25 | 4 | 89 | |
| CNTL 4 | 76 | 96 | 2 | 69 | 27 | 41 | |
| OKT3 1 | 88 | 99 | 0 | 51 | 95 | 0 | |
| 2698 | CNTL 1 | 94 | 98 | 2 | 39 | 51 | 36 |
| CNTL 2 | 86 | 90 | 8 | 48 | 10 | 81 | |
| CNTL 3 | 96 | 97 | 3 | 20 | 72 | 20 | |
| OKT3 1 | 94 | 100 | 0 | 54 | 99 | 0 | |
| OKT3 2 | 98 | 100 | 0 | 38 | 99 | 0 | |
| OKT3 3 | 96 | 100 | 0 | 39 | 98 | 0 | |
| 1321 | CNTL 1 | 18 | 1 | 94 | 84 | 1 | 95 |
| CNTL 2 | 8 | 1 | 94 | 73 | 0 | 97 | |
| OKT3 1 | 81 | 99 | 0 | 48 | 86 | 0 | |
| OKT3 2 | 74 | 99 | 0 | 54 | 86 | 0 | |
| OKT3 3 | 25 | 96 | 0 | 58 | 91 | 0 | |
| 1323 | CNTL 1 | 8 | 18 | 74 | 46 | 19 | 73 |
| CNTL 2 | 10 | 11 | 84 | 56 | 9 | 80 | |
| OKT3 1 | 7 | 92 | 0 | 18 | 86 | 0 | |
| AML no. . | Mouse . | BM . | SPL . | ||||
|---|---|---|---|---|---|---|---|
| Human . | AML . | T . | Human . | AML . | T . | ||
| 1658 | CNTL 1 | 16 | 13 | 81 | 23 | 4 | 82 |
| CNTL 2 | 46 | 13 | 81 | 20 | 4 | 83 | |
| CNTL 3 | 61 | 36 | 57 | 97 | 7 | 54 | |
| OKT3 1 | 42 | 98 | 0 | 1 | 92 | 0 | |
| OKT3 2 | 34 | 99 | 0 | 3 | 97 | 0 | |
| 2837 | CNTL 1 | 30 | 61 | 7 | 3 | 47 | 39 |
| CNTL 2 | 36 | 99 | 0 | 9 | 100 | 0 | |
| OKT3 1 | 37 | 100 | 0 | 1 | 100 | 0 | |
| OKT3 2 | 35 | 99 | 0 | 5 | 99 | 0 | |
| 2844 | CNTL 1 | 81 | 93 | 3 | 91 | 33 | 49 |
| CNTL 2 | 86 | 98 | 1 | 30 | 76 | 19 | |
| CNTL 3 | 92 | 59 | 37 | 25 | 4 | 89 | |
| CNTL 4 | 76 | 96 | 2 | 69 | 27 | 41 | |
| OKT3 1 | 88 | 99 | 0 | 51 | 95 | 0 | |
| 2698 | CNTL 1 | 94 | 98 | 2 | 39 | 51 | 36 |
| CNTL 2 | 86 | 90 | 8 | 48 | 10 | 81 | |
| CNTL 3 | 96 | 97 | 3 | 20 | 72 | 20 | |
| OKT3 1 | 94 | 100 | 0 | 54 | 99 | 0 | |
| OKT3 2 | 98 | 100 | 0 | 38 | 99 | 0 | |
| OKT3 3 | 96 | 100 | 0 | 39 | 98 | 0 | |
| 1321 | CNTL 1 | 18 | 1 | 94 | 84 | 1 | 95 |
| CNTL 2 | 8 | 1 | 94 | 73 | 0 | 97 | |
| OKT3 1 | 81 | 99 | 0 | 48 | 86 | 0 | |
| OKT3 2 | 74 | 99 | 0 | 54 | 86 | 0 | |
| OKT3 3 | 25 | 96 | 0 | 58 | 91 | 0 | |
| 1323 | CNTL 1 | 8 | 18 | 74 | 46 | 19 | 73 |
| CNTL 2 | 10 | 11 | 84 | 56 | 9 | 80 | |
| OKT3 1 | 7 | 92 | 0 | 18 | 86 | 0 | |
Mice were engrafted with samples with GVHD potential either with or without OKT3 preincubation. At sacrifice, flow cytometry was performed on BM and spleen (SPL) samples to determine total human engraftment and the percentage of CD45+CD3+ (T), CD45+CD33+ (AML), or CD45+CD19+ (ALL) within the human graft. NSG or NRG mice were used for B-ALL samples, and NSGS or NRGS mice were used for AML samples.